Dexanabinol has been studied in IV administration and oral dosing. e-Therapeutics is evaluating the compound in clinical trials for brain and solid cancers. Phase II studies are planned based on the results of the current trials.
"HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol)" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.
^Biegon A; Joseph AB (August 1995). "Development of HU-211 as a neuroprotectant for ischemic brain damage". Neurological Research17 (4): 275–80. PMID7477742.
^Darlington CL (October 2003). "Dexanabinol: a novel cannabinoid with neuroprotective properties". IDrugs : the Investigational Drugs Journal6 (10): 976–9. PMID14534855.
^Vink R; Nimmo AJ (January 2009). "Multifunctional drugs for head injury". Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics6 (1): 28–42. doi:10.1016/j.nurt.2008.10.036. PMID19110197.
^Maas AI et al. (January 2006). "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial". Lancet Neurol5 (1): 38–45. doi:10.1016/S1474-4422(05)70253-2. PMID16361021.CS1 maint: Explicit use of et al. (link)